Potent bivalent inhibition of human tryptase-β by a synthetic inhibitor

Biological Chemistry

Volumn 384, Issue 12, 2003, Pages 1605-1611

  Selwood, Trevor ^a   Elrod, Kyle C ^b   Schechter, Norman M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CELERA   (United States)

Author keywords

Dibasic; Inhibition; Protease; Tetramer; Therapeutic; Tight binding

Indexed keywords

4 AMINOBENZAMIDINE; CRA 2059; GUANIDINE DERIVATIVE; TRYPTASE; TRYPTASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DISSOCIATION CONSTANT; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG STRUCTURE; ENERGY TRANSFER; ENZYME BINDING; ENZYME INHIBITION; ENZYME KINETICS; HUMAN; PRIORITY JOURNAL; STOICHIOMETRY;

BENZAMIDINES; BINDING SITES; BINDING, COMPETITIVE; CROSS-LINKING REAGENTS; DIOXOLES; FLUORESCENT DYES; GUANIDINES; HUMANS; HYMECROMONE; KINETICS; OSMOLAR CONCENTRATION; PROTEIN BINDING; RECOMBINANT PROTEINS; SERINE ENDOPEPTIDASES; SERINE PROTEINASE INHIBITORS; SPECTROMETRY, FLUORESCENCE; SULFONES; THERMODYNAMICS; TRYPTASES;

EID: 0346728517     PISSN: 14316730     EISSN: None     Source Type: Journal    
DOI: 10.1515/BC.2003.178     Document Type: Article

References (27)

1. Burgess, L.E., Newhouse, B.J., Ibrahim, P., Rizzi, J., Kashem, M.A., Hartman, A., Brandhuber, B.J., Wright, C.D., Thomson, D.S., Vigers, G.P.A., and Koch, K. (1999). Potent selective inhibitors of human lung tryptase. Proc. Natl. Acad. Sci. USA 96, 8348-8352.
2. Caughey, G.H., ed. (1995). Mast Cell Proteases in Immunolgy and Biology (New York, USA: Marcel Dekker).
3. 2-terminal sequence, immuno-cytochemical localization, and specificity with prohormone and fluorogenic substrates. J. Biol. Chem. 262, 1363-1373.
4. Dener, J.M., Wang, V.R., Rice, K.D., Gangloff, A.R., Kuo, E.Y.-L., Newcomb, W.S., Putnam, D., and Wong, M. (2001). Monocharged inhibitors of mast cell tryptase derived from potent and selective dibasic inhibitors. Bioorg. Med. Chem. Lett. 11, 2325-2330.
5. Fersht, A.R. (1998). Enzyme structure and mechanism in protein science (New York, USA: W.H. Freeman).
6. Jameson, G.W., Roberts, D.V., Adams, R.W., Kyle, W.S.A., and Elmore, D.T. (1973). Determination of the operational molarity of solutions of bovine α-chymotrypsin, trypsin, thrombin and factor Xa by spectrofluorimetric titration. Biochem. J. 131, 107-117.
7. Kuzmic, P., Sideris, S., Cregar, L.M., Elrod, K.C., Rice, K.D., and Janc, J.W. (2000). High-throughput screening of enzyme inhibitors: automatic determination of tight-binding inhibition constants. Anal. Biochem. 281, 62-67.
8. Mammen, M., Choi, S.-K., and Whitesides, G.M. (1998). Polyvalent interaction in biological systems: implications for the design and use of multivalent ligands and inhibitors. Angew. Chem. Int. Ed. 37, 2755-2794.
9. Molinari, J.F., Moore, W.R., Clark, J., Tanaka, R., Butterfield, J.H., and Abraham, W.M. (1995). Role of tryptase in immediate cutaneous responses in allergic sheep. J. Appl. Physiol. 79, 1966-1970.
10. Molinari, J.F., Scuri, M., Moore, W.R., Clark, J., Tanaka, R., and Abraham, W.M. (1996). Inhaled tryptase causes bronchoconstriction in sheep via histamine release. Am. J. Respir. Crit. Care Med. 154, 649-653.
11. Morrison, J.F., and Walsh, C.T. (1988). The behavior and significance of slow-binding enzyme inhibitors. Adv. Enzymol. Relat. Areas Mol. Biol. 61, 201-301.
12. Newhouse, B.J. (2002). Tryptase inhibitors-review of the recent patent literature. IDrugs 5, 682-688.
13. Ono, S., Kuwahara, S., Takeuchi, M., H., S., Naito, Y., and Kondo, T. (1999). Syntheses and evaluation of aminobenzofuran derivatives as tryptase inhibitors. Bioorg. Med. Chem. Lett. 9, 3285-3290.
14. Pereira, P.J.B., Bergner, A., Macedo-Ribeiro, S., Huber, R., Matschiner, G., Fritz, H., Sommerhoff, C.P., and Bode, W. (1998). Human β-tryptase is a ring-like tetramer with active sites facing a central pore. Nature 392, 306-311.
15. Record, M.T., Anderson, C.F., and Lohman, T.M. (1978). Thermodynamic analysis of ion effects on the binding and conformational equilibria of proteins and nucleic acids: the roles of ion association, screening and ion effects on water activity. Q. Rev. Biophys. 2, 103-178.
16. Rice, K.D., Gangloff, A.R., Kuo, E.Y.-L., Dener, J.M., Wang, V.R., Lum, R., Newcomb, W.S., Havel, C., Putnam, D., Cregar, L., Wong, M., and Warne, R.L. (2000a). Dibasic inhibitors of human mast cell tryptase. Part 1: synthesis and optimization of a novel class of inhibitors. Bioorg. Med. Chem. Lett. 10, 2357-2360.
17. Rice, K.D., and Sprengler, P.A. (1999). Therapeutic applications and design of mast cell tryptase inhibitors. Curr. Opin. Drug Discov. Dev. 2, 463-474.
18. Rice, K.D., Wang, V.R., Gangloff, A.R., Kuo, E.Y.-L., Dener, J.M., Newcomb, W.S., Young, W.B., Putnam, D., Cregar, L., Wong, M., and Simpson, P.J. (2000b). Dibasic inhibitors of human mast cell tryptase. Part 2: structure activity relationships and requirements for potent activity. Bioorg. Med. Chem. Lett. 10, 2361-2366.
19. Schaschke, N., Matschiner, G., Zettl, F., Marquardt, U., Bergner, A., Bode, W., Sommerhoff, C.P., and Moroder, L. (2001). Bivalent inhibition of human β-tryptase. Chem. Biol. 8, 313-327.
20. Schaschke, N., Dominik, A., Matschiner, G., and Sommerhoff, C.P. (2002). Bivalent inhibition of β-tryptase: distance scan of neighboring subunits by dibasic inhibitors. Bioorg. Med. Chem. Lett. 12, 985-988.
21. Schechter, N.M., Eng, G.Y., Selwood, T., and McCaslin, D.R. (1995). Structural changes associated with the spontaneous inactivation of the serine proteinase human tryptase. Biochemistry 34, 10628-10638.
22. Schwartz, L.B., Lewis, R.A., and Austen, K.F. (1981). Tryptase from human pulmonary mast cells-purification and characterization. J. Biol. Chem. 256, 11939-11943.
23. Schwartz, L.B., Irani, A.-M.A., Roller, K., Castells, M.C., and Schechter, N.M. (1987). Quantification of histamine, tryptase, and chymase in dispersed human T and TC mast cells. J. Immunol. 138, 2611-2615.
24. Selwood, T., McCaslin, D.R., and Schechter, N.M. (1998). Spontaneous inactivation of human tryptase involves conformational changes consistent with conversion of the active site to a zymogen-like structure. Biochemistry 37, 13174-13183.
25. Selwood, T., Wang, Z.-M., McCaslin, D.R., and Schechter, N.M. (2002). Diverse stability and catalytic properties of human tryptase α and β isoforms are mediated by residue differences at the S1 pocket. Biochemistry 41, 3329-3340.
26. Tremaine, W.J., Brzezinski, J.A., Katz, J.A., Wolf, D.C., Flemming, T.J., Mordenti, J., Strenkoski-Nix, L.C., Kurth, M.C., and Group, T.A.U.C.S. (2002). Treatment of mildly to moderately active ulcerative colitis with a tryptase inhibitor (APC 2059): an open-label pilot study. Aliment. Pharmacol. Ther. 16, 407-413.
27. Wang, Z.-M., Walter, M., Selwood, T., Rubin, H., and Schechter, N.M. (1998). Recombinant expression of human mast cell proteases chymase and tryptase. Biol. Chem. 379, 167-174.